Prospects and Limits of Pharmacogenetics: The Thiopurine Methyl Transferase (TPMT) Experience

Author： van Aken J.   Schmedders M.   Feuerstein G.   Kollek R.  

Publisher： Adis International

ISSN： 1175-2203

Source： American Journal of PharmacoGenomics, Vol.3, Iss.3, 2003-01, pp. : 149-155

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TPMT genotypes not predictive of thiopurine ADRs

By  

Inpharma, Vol. 1, Iss. 1409, 2003-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

Prospects for pharmacogenetics

By Roland W.C.  

International Journal of Pharmaceutical Medicine, Vol. 15, Iss. 2, 2001-04 ,pp. : 57-58

Adis International

Access to resources Recommend Favorite

Thiopurine methyltransferase (TPMT) genotype distribution in azathioprine-tolerant and -intolerant patients with various disorders. The impact of TPMT genotyping in predicting toxicity

By Reuther Lene   Vainer Ben   Sonne Jesper   Larsen Niels-Erik  

European Journal of Clinical Pharmacology, Vol. 59, Iss. 11, 2004-01 ,pp. : 797-801

Springer Publishing Company

Access to resources Recommend Favorite

Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?

By Higgs Jenny E   Payne Katherine   Roberts Chris   Newman William G  

Pharmacogenomics, Vol. 11, Iss. 2, 2010-02 ,pp. : 177-188

Future Medicine

Access to resources Recommend Favorite

Role of Monitoring Thiopurine Methyltransferase (TPMT) Activity in the Individualized Therapy with Azathioprine or 6-Mercaptopurine

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 6, Iss. 1, 2008-03 ,pp. : 33-44

Bentham Science Publishers

Access to resources Recommend Favorite